Sage Therapeutics (SAGE) Scheduled to Post Earnings on Tuesday

Sage Therapeutics (NASDAQ:SAGE) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, October 29th. Analysts expect Sage Therapeutics to post earnings of ($1.53) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.02). Sage Therapeutics had a negative return on equity of 55.87% and a negative net margin of 458.30%. The business had revenue of $8.65 million during the quarter, compared to analyst estimates of $8.85 million. During the same quarter last year, the firm earned ($2.68) EPS. Sage Therapeutics’s revenue for the quarter was up 249.8% compared to the same quarter last year. On average, analysts expect Sage Therapeutics to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Sage Therapeutics Stock Up 2.9 %

Shares of Sage Therapeutics stock opened at $7.79 on Tuesday. Sage Therapeutics has a twelve month low of $5.84 and a twelve month high of $28.26. The company has a 50-day simple moving average of $7.55 and a two-hundred day simple moving average of $10.35. The stock has a market capitalization of $475.58 million, a price-to-earnings ratio of -1.05 and a beta of 0.91.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Bank of America dropped their price objective on shares of Sage Therapeutics from $11.00 to $6.00 and set an “underperform” rating for the company in a research note on Wednesday, October 9th. Robert W. Baird dropped their target price on shares of Sage Therapeutics from $13.00 to $9.00 and set a “neutral” rating for the company in a research report on Wednesday, October 9th. HC Wainwright restated a “neutral” rating and issued a $25.00 target price on shares of Sage Therapeutics in a research report on Wednesday, October 9th. TD Cowen cut shares of Sage Therapeutics from a “buy” rating to a “hold” rating and dropped their target price for the company from $16.00 to $10.00 in a research report on Tuesday, July 30th. Finally, Wedbush dropped their target price on shares of Sage Therapeutics from $9.00 to $8.00 and set a “neutral” rating for the company in a research report on Wednesday, October 9th. Two research analysts have rated the stock with a sell rating, eighteen have issued a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Sage Therapeutics has a consensus rating of “Hold” and an average target price of $13.76.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.